About aTyr Pharma
aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Life Sciences Tools & Services
- Exchange: NASDAQ
- Symbol: LIFE
- CUSIP: 53217V10
- Previous Close: $3.38
- 50 Day Moving Average: $3.117
- 200 Day Moving Average: $3.034
- 52-Week Range: $23,718,000.00 - $2.10
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.34
- P/E Growth: 0.000
- Market Cap: $80.05M
- Outstanding Shares: 23,718,000
- Beta: 3.52
- Return on Equity: -65.72%
- Return on Assets: -57.31%
Companies Related to aTyr Pharma:
- Current Ratio: 6.17%
- Quick Ratio: 6.17%
What is aTyr Pharma's stock symbol?
aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE."
Where is aTyr Pharma's stock going? Where will aTyr Pharma's stock price be in 2017?
4 brokerages have issued twelve-month price targets for aTyr Pharma's stock. Their forecasts range from $2.85 to $4.00. On average, they anticipate aTyr Pharma's share price to reach $3.62 in the next year.
When will aTyr Pharma announce their earnings?
aTyr Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, March, 28th 2017.
Who owns aTyr Pharma stock?
aTyr Pharma's stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Alyeska Investment Group L.P. (4.52%), EcoR1 Capital LLC (4.12%) and Dimensional Fund Advisors LP (0.23%). Company insiders that own aTyr Pharma stock include Ashraf Amanullah, Grove Matsuoka, James E Flynn, John Mendlein, Paul Schimmel and Sofinnova Venture Partners Ix,.
Who bought aTyr Pharma stock? Who is buying aTyr Pharma stock?
aTyr Pharma's stock was purchased by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC and Alyeska Investment Group L.P.. Company insiders that have bought aTyr Pharma stock in the last two years include Ashraf Amanullah, Grove Matsuoka, James E Flynn, John Mendlein, Paul Schimmel and Sofinnova Venture Partners Ix,.
How do I buy aTyr Pharma stock?
Shares of aTyr Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of aTyr Pharma stock cost?
One share of aTyr Pharma stock can currently be purchased for approximately $3.38.